Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Blood Reviews
|
September 30, 2025
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
Ali Mushtaq, Asfand Yar Cheema, Hossam M Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 27, 2025
Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey
Hossam M Ali, Zainab Yusufali Motiwala, Yara Shatnawi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
Rakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 9, 2025
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
American Journal of Hematology
|
March 16, 2022
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study
Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 20, 2024
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood
|
May 12, 2026
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis
Efstathios Kastritis, Giovanni Palladini, Monique C Minnema, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Blood Reviews
|
September 30, 2025
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
Ali Mushtaq, Asfand Yar Cheema, Hossam M Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 27, 2025
Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey
Hossam M Ali, Zainab Yusufali Motiwala, Yara Shatnawi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
Rakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 9, 2025
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
American Journal of Hematology
|
March 16, 2022
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study
Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 20, 2024
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood
|
May 12, 2026
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis
Efstathios Kastritis, Giovanni Palladini, Monique C Minnema, et al.
Page
of 9